Sitagliptin Phosphate & Metformin Hydrochloride Tablets - ZELVIA M 50/1000 Tablets

ZELVIA M 50/1000 Tablets  – Advanced Diabetes Care with Lasting Glycemic Control & Improved Tolerability.

ZELVIA M 50/1000 Tablets – Sitagliptin Phosphate & Metformin Hydrochloride Tablets is a dual-acting oral antidiabetic formulation combining Sitagliptin, a DPP-4 inhibitor, and Metformin, a biguanide, designed to manage Type 2 Diabetes Mellitus effectively.
Sitagliptin enhances levels of active incretins, stimulating glucose-dependent insulin secretion and lowering glucagon levels, thereby reducing hepatic glucose production.
Metformin works by decreasing hepatic glucose output and increasing peripheral insulin sensitivity. 
This combination supports comprehensive glycemic control, helps lower HbA1c levels, and is also suitable for patients with cardiometabolic risks due to its weight-neutral and cardiovascular-safe profile.

Key Benefits of  Sitagliptin Phosphate & Metformin Hydrochloride Tablets – ZELVIA M 50/1000 Tablets
✅Dual Mechanism for Effective action – Sitagliptin and Metformin work synergistically by dual mechanisms to improve insulin action and reduce glucose production.
✅Prolonged-Release for Better Tolerance – Provides a steady release of Metformin, minimizing GI upset and enhancing patient compliance.
✅Improved Safety Profile – This combination tablet has a lower risk of hypoglycemia and better tolerance compared to sulfonylureas or insulin-based therapies.

Recommended by Specialists:
👨‍⚕️Diabetologists – To target type 2 diabetes mellitus and as part of combination therapy to improve insulin sensitivity and enhance incretin response.
👨‍⚕️General Physicians – For routine management of adults with poorly controlled diabetes requiring both fasting and postprandial glucose control.
👨‍⚕️Cardiologists – In diabetic patients with heart-related risk factors, due to Sitagliptin’s cardiovascular tolerability and weight neutrality.

Indications:
✅Type 2 Diabetes Mellitus
✅Cardiometabolic Risk Management